SE0103819D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0103819D0
SE0103819D0 SE0103819A SE0103819A SE0103819D0 SE 0103819 D0 SE0103819 D0 SE 0103819D0 SE 0103819 A SE0103819 A SE 0103819A SE 0103819 A SE0103819 A SE 0103819A SE 0103819 D0 SE0103819 D0 SE 0103819D0
Authority
SE
Sweden
Prior art keywords
chemical compounds
compounds
compositions
preparing
processes
Prior art date
Application number
SE0103819A
Other languages
English (en)
Swedish (sv)
Inventor
John Cumming
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103819A priority Critical patent/SE0103819D0/xx
Publication of SE0103819D0 publication Critical patent/SE0103819D0/xx
Priority to TW091132377A priority patent/TW200407140A/zh
Priority to RU2004112781/04A priority patent/RU2004112781A/ru
Priority to EP02786316A priority patent/EP1448524A1/en
Priority to CNA028227409A priority patent/CN1589261A/zh
Priority to HU0402567A priority patent/HUP0402567A2/hu
Priority to MXPA04004497A priority patent/MXPA04004497A/es
Priority to US10/495,405 priority patent/US20050014788A1/en
Priority to PCT/SE2002/002054 priority patent/WO2003042177A1/en
Priority to JP2003544013A priority patent/JP2005513017A/ja
Priority to ARP020104332A priority patent/AR037350A1/es
Priority to IL16159402A priority patent/IL161594A0/xx
Priority to CA002464861A priority patent/CA2464861A1/en
Priority to BR0214141-8A priority patent/BR0214141A/pt
Priority to PL02370910A priority patent/PL370910A1/xx
Priority to KR10-2004-7007365A priority patent/KR20050013526A/ko
Priority to IS7257A priority patent/IS7257A/is
Priority to ZA200403681A priority patent/ZA200403681B/en
Priority to NO20042156A priority patent/NO20042156L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
SE0103819A 2001-11-15 2001-11-15 Chemical compounds SE0103819D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0103819A SE0103819D0 (sv) 2001-11-15 2001-11-15 Chemical compounds
TW091132377A TW200407140A (en) 2001-11-15 2002-11-01 Chemical compounds
KR10-2004-7007365A KR20050013526A (ko) 2001-11-15 2002-11-12 피페리딘 유도체 및 그의 케모킨 수용체 활성의조절제로서의 용도 (특히 ｃｃｒ5)
PCT/SE2002/002054 WO2003042177A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
IL16159402A IL161594A0 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
CNA028227409A CN1589261A (zh) 2001-11-15 2002-11-12 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
HU0402567A HUP0402567A2 (hu) 2001-11-15 2002-11-12 Piperidinszármazékok és alkalmazásuk kemokin receptor (különösen CCR5) aktivitás modulátoraiként
MXPA04004497A MXPA04004497A (es) 2001-11-15 2002-11-12 Derivados de piperidina y su uso como moduladores de actividad del receptor de quimiocina (especialmente ccr5).
US10/495,405 US20050014788A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
RU2004112781/04A RU2004112781A (ru) 2001-11-15 2002-11-12 Производные пиперидина и их применение в качестве модуляторов активности рецепторов хемокинов (в частности ccr5)
JP2003544013A JP2005513017A (ja) 2001-11-15 2002-11-12 ケモカイン受容体（特にｃｃｒ）活性のモジュレーターとしてのピペリジン誘導体とその使用
ARP020104332A AR037350A1 (es) 2001-11-15 2002-11-12 Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea)
EP02786316A EP1448524A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
CA002464861A CA2464861A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
BR0214141-8A BR0214141A (pt) 2001-11-15 2002-11-12 Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
PL02370910A PL370910A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
IS7257A IS7257A (is) 2001-11-15 2004-05-10 Píperidínafleiður og notkun þeirra sem stilla á virkni flakkboðaviðtaka (einkum CCR5)
ZA200403681A ZA200403681B (en) 2001-11-15 2004-05-13 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5).
NO20042156A NO20042156L (no) 2001-11-15 2004-05-25 Piperidinderivater og deres anvendelse som modulatorer av kemokinreseptoraktivitet (spesielt CCRS)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103819A SE0103819D0 (sv) 2001-11-15 2001-11-15 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0103819D0 true SE0103819D0 (sv) 2001-11-15

Family

ID=20286006

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103819A SE0103819D0 (sv) 2001-11-15 2001-11-15 Chemical compounds

Country Status (19)

Country Link
US (1) US20050014788A1 (enExample)
EP (1) EP1448524A1 (enExample)
JP (1) JP2005513017A (enExample)
KR (1) KR20050013526A (enExample)
CN (1) CN1589261A (enExample)
AR (1) AR037350A1 (enExample)
BR (1) BR0214141A (enExample)
CA (1) CA2464861A1 (enExample)
HU (1) HUP0402567A2 (enExample)
IL (1) IL161594A0 (enExample)
IS (1) IS7257A (enExample)
MX (1) MXPA04004497A (enExample)
NO (1) NO20042156L (enExample)
PL (1) PL370910A1 (enExample)
RU (1) RU2004112781A (enExample)
SE (1) SE0103819D0 (enExample)
TW (1) TW200407140A (enExample)
WO (1) WO2003042177A1 (enExample)
ZA (1) ZA200403681B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0202483D0 (sv) * 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (sv) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
EP1654229B1 (en) * 2003-07-31 2007-05-09 AstraZeneca AB Piperidine derivatives as ccr5 receptor modulators
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
SE0303396D0 (sv) * 2003-12-16 2003-12-16 Astrazeneca Ab Chemical compounds
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
KR100905260B1 (ko) 2004-06-09 2009-06-30 상해 타킷 드러그 주식회사 씨씨알5 길항제로서의 화합물
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401657D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2173715A2 (en) * 2007-07-13 2010-04-14 Euroscreen S.A. Use of piperidine derivatives as agonists of chemokine receptor activity
CN105579555A (zh) * 2013-09-25 2016-05-11 默克专利股份有限公司 化合物和介晶介质

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004200A3 (en) * 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
TW200407140A (en) 2004-05-16
CN1589261A (zh) 2005-03-02
HUP0402567A2 (hu) 2005-03-29
US20050014788A1 (en) 2005-01-20
PL370910A1 (en) 2005-05-30
MXPA04004497A (es) 2004-08-11
CA2464861A1 (en) 2003-05-22
AR037350A1 (es) 2004-11-03
RU2004112781A (ru) 2005-10-10
KR20050013526A (ko) 2005-02-04
ZA200403681B (en) 2005-08-02
NO20042156L (no) 2004-08-11
BR0214141A (pt) 2004-10-19
WO2003042177A1 (en) 2003-05-22
JP2005513017A (ja) 2005-05-12
EP1448524A1 (en) 2004-08-25
IL161594A0 (en) 2004-09-27
WO2003042177A8 (en) 2005-01-06
IS7257A (is) 2004-05-10

Similar Documents

Publication Publication Date Title
SE0103818D0 (sv) Chemical compounds
TW200630326A (en) Chemical compounds
MXPA02011304A (es) Derivados de piperidina farmaceuticamente activos, en partiular como moduladores de la actividad del receptor de la quimocina.
TW200505856A (en) Chemical compounds
SE0101387D0 (sv) Novel compounds
SE9904505D0 (sv) Novel compounds
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TW200610761A (en) Chemical compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2003042177A8 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
NO20070431L (no) Kjemiske forbindelser I
DE60001586D1 (de) Diphenyl-piperidin derivate
SE0301369D0 (sv) Chemical compounds
SE0402635D0 (sv) Chemical compounds
SE0401656D0 (sv) Chemical compounds
DE60201259D1 (de) Chemische verbindungen
SE0203828D0 (sv) Chemical compounds
SE0203820D0 (sv) chemical compounds
SE0302090D0 (sv) Chemical compounds
SE0303396D0 (sv) Chemical compounds
TW200510307A (en) Chemical compounds
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
SE0402636D0 (sv) Chemical compounds
SE0401057D0 (sv) Chemical Compounds
SE0403106D0 (sv) Chemical compounds